The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens-Reference-Cited by-同舟云学术

The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens

Published:2010-11-18 Issue:9 Volume:117 Page:1884-1890
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Benevolo Giulia,Larocca Alessandra,Gentile Massimo,Pregno Patrizia,Gay Francesca,Botto Barbara,Frairia Chiara,Evangelista Andrea,Morabito Fortunato,Boccadoro Mario,Vitolo Umberto,Palumbo Antonio

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.25743/fullpdf

Reference38 articles.

1. Cancer incidence and mortality in Europe, 2004;Boyle;Ann Oncol.,2005

2. InterGroupe Francophone du Myelome. Single versus double autologous stem-cell transplantation for multiple myeloma;Attal;N Engl J Med.,2003

3. Medical Research Council Adult Leukaemia Working Party. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma;Child;N Engl J Med.,2003

4. Antitumor activity of thalidomide in refractory multiple myeloma;Singhal;N Engl J Med.,1999

5. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group;Rajkumar;J Clin Oncol.,2006

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study;Blood Cancer Journal;2020-05

2. Saquinavir plus methylprednisolone ameliorates experimental acute lung injury;Brazilian Journal of Medical and Biological Research;2018

3. Exposure–safety–efficacy analysis of single-agent ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma: dose selection for a phase 3 maintenance study;Investigational New Drugs;2016-04-02

4. Expressions of miR-181a and miR-20a in RPMI8226 cell line and their potential as biomarkers for multiple myeloma;Tumor Biology;2015-06-02

5. Proteasome inhibitors increase missense mutated dysferlin in patients with muscular dystrophy;Science Translational Medicine;2014-08-20